Nuvectis Pharma Inc (NVCT)
6.72
+0.13
(+1.97%)
USD |
NASDAQ |
Apr 24, 16:00
6.72
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 119.41M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -52.52% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | -- |
Price to Book Value | 9.787 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
Profile
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900. |
URL | https://www.nuvectis.com |
Investor Relations URL | https://nuvectis.com/investors-and-media/ |
HQ State/Province | New Jersey |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | N/A |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | Nov. 08, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900. |
URL | https://www.nuvectis.com |
Investor Relations URL | https://nuvectis.com/investors-and-media/ |
HQ State/Province | New Jersey |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | N/A |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | Nov. 08, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |